Pregabalin Mylan Pharma

Pays: Union européenne

Langue: anglais

Source: EMA (European Medicines Agency)

Achète-le

Ingrédients actifs:

pregabalin

Disponible depuis:

Mylan S.A.S.

Code ATC:

N03AX16

DCI (Dénomination commune internationale):

pregabalin

Groupe thérapeutique:

Antiepileptics,

Domaine thérapeutique:

Anxiety Disorders; Neuralgia; Epilepsy

indications thérapeutiques:

EpilepsyPregabalin Mylan Pharma is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.Generalised Anxiety DisorderPregabalin Mylan Pharma is indicated for the treatment of Generalised Anxiety Disorder (GAD) in adults.

Descriptif du produit:

Revision: 7

Statut de autorisation:

Withdrawn

Date de l'autorisation:

2015-06-25

Notice patient

                                64
B. PACKAGE LEAFLET
Medicinal Product no longer authorised
65
PACKAGE LEAFLET: INFORMATION FOR THE USER
PREGABALIN MYLAN PHARMA 25 MG HARD CAPSULES
PREGABALIN MYLAN PHARMA 50 MG HARD CAPSULES
PREGABALIN MYLAN PHARMA 75 MG HARD CAPSULES
PREGABALIN MYLAN PHARMA 100 MG HARD CAPSULES
PREGABALIN MYLAN PHARMA 150 MG HARD CAPSULES
PREGABALIN MYLAN PHARMA 200 MG HARD CAPSULES
PREGABALIN MYLAN PHARMA 225 MG HARD CAPSULES
PREGABALIN MYLAN PHARMA 300 MG HARD CAPSULES
pregabalin
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Pregabalin Mylan Pharma is and what it is used for
2.
What you need to know before you take Pregabalin Mylan Pharma
3.
How to take Pregabalin Mylan Pharma
4.
Possible side effects
5.
How to store Pregabalin Mylan Pharma
6.
Contents of the pack and other information
1.
WHAT PREGABALIN MYLAN PHARMA IS AND WHAT IT IS USED FOR
Pregabalin Mylan Pharma contains the active substance pregabalin which
belongs to a group of
medicines used to treat epilepsy and Generalised Anxiety Disorder
(GAD) in adults.
EPILEPSY:
Pregabalin Mylan Pharma is used to treat a certain form of epilepsy
(partial seizures with or
without secondary generalisation) in adults. Your doctor will
prescribe Pregabalin Mylan Pharma for
you to help treat your epilepsy when your current treatment is not
controlling your condition. You
should take Pregabalin Mylan Pharma in addition to your current
treatment. Pregabalin Mylan Pharma
is not intended to be used alone, but should always be used in
combination with other anti-epil
                                
                                Lire le document complet
                                
                            

Résumé des caractéristiques du produit

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
Medicinal Product no longer authorised
2
1.
NAME OF THE MEDICINAL PRODUCT
Pregabalin Mylan Pharma 25 mg hard capsules
Pregabalin Mylan Pharma 50 mg hard capsules
Pregabalin Mylan Pharma 75 mg hard capsules
Pregabalin Mylan Pharma 100 mg hard capsules
Pregabalin Mylan Pharma 150 mg hard capsules
Pregabalin Mylan Pharma 200 mg hard capsules
Pregabalin Mylan Pharma 225 mg hard capsules
Pregabalin Mylan Pharma 300 mg hard capsules
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Pregabalin Mylan Pharma 25 mg hard capsules
Each hard capsule contains 25 mg of pregabalin.
Pregabalin Mylan Pharma 50 mg hard capsules
Each hard capsule contains 50 mg of pregabalin.
Pregabalin Mylan Pharma 75 mg hard capsules
Each hard capsule contains 75 mg of pregabalin.
Pregabalin Mylan Pharma 100 mg hard capsules
Each hard capsule contains 100 mg of pregabalin.
Pregabalin Mylan Pharma 150 mg hard capsules
Each hard capsule contains 150 mg of pregabalin.
Pregabalin Mylan Pharma 200 mg hard capsules
Each hard capsule contains 200 mg of pregabalin.
Pregabalin Mylan Pharma 225 mg hard capsules
Each hard capsule contains 225 mg of pregabalin.
Pregabalin Mylan Pharma 300 mg hard capsules
Each hard capsule contains 300 mg of pregabalin.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Hard capsule.
Pregabalin Mylan Pharma 25 mg hard capsules
Medicinal Product no longer authorised
3
No. 4, light peach opaque cap and white opaque body, hard-shell
gelatin capsule filled with
white to off-white powder. The capsule is axially printed with MYLAN
over PB25 in black ink
on cap and body.
Pregabalin Mylan Pharma 50 mg hard capsules
The 50 mg capsules are No. 3, dark peach opaque cap and white opaque
body, hard-shell gelatin
capsule filled with white to off-white powder. The capsule is axially
printed with MYLAN over
PB50 in black ink on cap and body.
Pregabalin Mylan Pharma 75 mg hard capsules
The 75 mg capsules are No. 4, light peach opaque cap and light peach
opaque body, hard-shell
gelat
                                
                                Lire le document complet
                                
                            

Documents dans d'autres langues

Notice patient Notice patient bulgare 26-04-2022
Rapport public d'évaluation Rapport public d'évaluation bulgare 26-04-2022
Notice patient Notice patient espagnol 26-04-2022
Rapport public d'évaluation Rapport public d'évaluation espagnol 26-04-2022
Notice patient Notice patient tchèque 26-04-2022
Rapport public d'évaluation Rapport public d'évaluation tchèque 26-04-2022
Notice patient Notice patient danois 26-04-2022
Rapport public d'évaluation Rapport public d'évaluation danois 26-04-2022
Notice patient Notice patient allemand 26-04-2022
Rapport public d'évaluation Rapport public d'évaluation allemand 26-04-2022
Notice patient Notice patient estonien 26-04-2022
Rapport public d'évaluation Rapport public d'évaluation estonien 26-04-2022
Notice patient Notice patient grec 26-04-2022
Notice patient Notice patient français 26-04-2022
Rapport public d'évaluation Rapport public d'évaluation français 26-04-2022
Notice patient Notice patient italien 26-04-2022
Rapport public d'évaluation Rapport public d'évaluation italien 26-04-2022
Notice patient Notice patient letton 26-04-2022
Rapport public d'évaluation Rapport public d'évaluation letton 26-04-2022
Notice patient Notice patient lituanien 26-04-2022
Rapport public d'évaluation Rapport public d'évaluation lituanien 26-04-2022
Notice patient Notice patient hongrois 26-04-2022
Rapport public d'évaluation Rapport public d'évaluation hongrois 26-04-2022
Notice patient Notice patient maltais 26-04-2022
Rapport public d'évaluation Rapport public d'évaluation maltais 26-04-2022
Notice patient Notice patient néerlandais 26-04-2022
Rapport public d'évaluation Rapport public d'évaluation néerlandais 26-04-2022
Notice patient Notice patient polonais 26-04-2022
Rapport public d'évaluation Rapport public d'évaluation polonais 26-04-2022
Notice patient Notice patient portugais 26-04-2022
Rapport public d'évaluation Rapport public d'évaluation portugais 26-04-2022
Notice patient Notice patient roumain 26-04-2022
Rapport public d'évaluation Rapport public d'évaluation roumain 26-04-2022
Notice patient Notice patient slovaque 26-04-2022
Rapport public d'évaluation Rapport public d'évaluation slovaque 26-04-2022
Notice patient Notice patient slovène 26-04-2022
Rapport public d'évaluation Rapport public d'évaluation slovène 26-04-2022
Notice patient Notice patient finnois 26-04-2022
Rapport public d'évaluation Rapport public d'évaluation finnois 26-04-2022
Notice patient Notice patient suédois 26-04-2022
Rapport public d'évaluation Rapport public d'évaluation suédois 26-04-2022
Notice patient Notice patient norvégien 26-04-2022
Notice patient Notice patient islandais 26-04-2022
Notice patient Notice patient croate 26-04-2022
Rapport public d'évaluation Rapport public d'évaluation croate 26-04-2022

Rechercher des alertes liées à ce produit

Afficher l'historique des documents